TITLE

ORAMORPH FOR BREATHLESSNESS: IN PURSUIT OF GUIDELINES AND PATIENT INFORMATION FOR USE IN COPD

AUTHOR(S)
Williamson, A.; Restrick, L.; Potter, C.; Purcell, S.; Roberts, S.; Coleman, B.; Stern, M.
PUB. DATE
December 2011
SOURCE
Thorax;Dec2011 Supplement, pA174
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Introduction Breathlessness is the most common and frightening symptom in Chronic Obstructive Pulmonary Disease (COPD). Short-acting morphine (Oramorph) has traditionally been used to treat breathlessness in palliative care. Although used in COPD (Simon et al, 2010), there is no consensus/guidelines for prescribing and patients stigmatise morphine, associating it with dying or addiction. In this study, we assessed current prescribing practice, patient use and safety of Oramorph, to inform local prescribing guidelines and patient information. Method Case notes of patients who were prescribed Oramorph for breathlessness while having multidisciplinary COPD care between 2004 and 2011 were reviewed. The following were documented: patient demographics, disease severity (FEV1, MRC dyspnoea score, nebulisers, long term oxygen therapy (LTOT), domiciliary Non-Invasive Ventilation (NIV), social/healthcare support and palliative care referrals; Oramorph starting dosage, dosage range, increase in dosage, patient choice to continue, duration of and use of morphine sulphate slow release tablet (MST). Results 28 COPD patients prescribed Oramorph for breathlessness were identified (14 M), median (range) age 70 (52-83) years FEV1 (mean±SD) 0.58±0.22, MRC dyspnoea score 4.6±0.49. 19/28 (68%) were on LTOT, 28/28 (100%) on nebulisers, 5/28 (17%) on domiciliary NIV, two current smokers, 10/28 (36%) lived alone, 27/28 (96%) had professional healthcare domiciliary visits, 8/28 (29%) had palliative care input. Starting, incremental and current dosing of Oramorph are shown in the Abstract P262 table 1. 25/28 (89%) patients chose to stay on Oramorph once started. Median (range) duration on Oramorph was 8 months (45 days-7.5 years). MST was added for breathlessness in three patients. 13/28 (46%) patients died; all were MRC 5 and starting Oramorph was not felt to be a contributing factor by the clinical team. Time to death after starting Oramorph was median (range) 7 months (68 days-2.6 years). Oramorph prescribing in COPD increased year-on-year (one patient in 2004 to 12 in 2010). Conclusion Oramorph prescribed by a respiratory team for breathlessness is safe in this group of patients. This study indicates that its effect is sustained despite low dosages with little requirement for incremental dosing over time. Guidelines for prescribing and patient information will be critical to ensure that patients are not denied this useful treatment of breathlessness.
ACCESSION #
70237939

 

Related Articles

  • A RANDOMISED CONTROL TRIAL TO INVESTIGATE THE EFFECTIVENESS OF PLB IN THE CLINICAL SETTING. Roberts, S. E.; Schreuder, F. M.; Watson, T.; Stern, M. // Thorax;Dec2011 Supplement, pA175 

    Introduction Pursed lips breathing (PLB) at rest increases oxygen saturation and tidal volume and reduces respiratory rate. Used with exercise it shortens the recovery period, reduces end-exercise breathlessness and improves reported physical function measured by SF-36 (Roberts SE et al, 2009)....

  • Oxygen may reduce dyspnoea in people with COPD who have mild or no hypoxaemia. Stoller, James K. // Evidence Based Medicine;Apr2012, Vol. 17 Issue 2, p40 

    The author comments on a study by Uronis and colleagues which revealed that supplemental oxygen (SupplO2) can relieve dyspnoea in mildly and non-hypoxaemic people with chronic obstructive pulmonary disease (COPD). He mentions that the study failed to answer pressing clinical questions that...

  • Helping Patients with COPD Manage Episodes of Acute Shortness of Breath. Truesdell, Sandra // MEDSURG Nursing;Aug2000, Vol. 9 Issue 4, p178 

    Provides information on how to educate patients with chronic obstructive pulmonary disease in implementing pursed-lip breathing during acute episodes of dyspnea. Patient strategies for managing dyspnea; Efficacy of pursed-lip breathing in reducing dyspnea; Problems with pursed-lip breathing.

  • ASSESSING THE EDUCATIONAL IMPACT OF PULMONARY REHABILITATION IN NON-COPD PATIENTS USING THE LUNG INFORMATION NEEDS QUESTIONNAIRE. Fowler, R. P.; Ardelean, D.; Ingram, K. I.; Clark, A. L.; Marns, P. L.; Kon, S. S. C.; Canavan, J. L.; Man, W. D.-C. // Thorax;Dec2011 Supplement, pA16 

    Background There is increasing evidence to suggest that pulmonary rehabilitation (PR) improves exercise capacity, health status and dyspnoea in non-COPD chronic respiratory disease patients. However it is not clear how to assess the education component of PR on these patients. The Lung...

  • Chronic obstructive pulmonary disease. Whittaker, C. // South African Family Practice;Jan/Feb2013, Vol. 55 Issue 1, p20 

    Chronic obstructive pulmonary disease affects millions of people, has a major impact on quality of life and has become an important cause of death worldwide. Over the past decade, a better understanding of COPD has been gained, while research into new therapies and treatment strategies has...

  • Short of Breath and Dying. Lowey, Susan E.; Powers, Bethel Ann; Ying Xue // Journal of Gerontological Nursing;Feb2013, Vol. 39 Issue 2, p43 

    The purpose of this narrative literature review was to describe the state of the science on the effectiveness of opioid medications to palliate dyspnea in older adults with advanced disease. A three-stage critical appraisal process was used to evaluate articles published between 2000-2011 that...

  • OUTCOMES OF PULMONARY REHABILITATION IN SEVERE ASTHMA. Agbetile, J.; Singh, S.; Bradding, P.; Pavord, I.; Green, R. // Thorax;Dec2011 Supplement, pA127 

    Objectives Structured physical training programmes are a key component of pulmonary rehabilitation (PR) and have consistently been shown to be of significant benefit to patients with COPD. It is unclear whether the application of similar principles provides similar health improvements in...

  • Palliation of dyspnoea in advanced COPD: revisiting a role for opioids. Rocker, G.; Horton, R.; Currow, D.; Goodridge, D.; Young, J.; Booth, S. // Thorax;Oct2009, Vol. 64 Issue 10, p910 

    Chronic obstructive pulmonary disease (COPD) will be the third leading cause of death worldwide by 2020. The burdens of this increasingly prevalent illness borne by patients, their family caregivers and the healthcare system are substantial. Dyspnoea as the predominant symptom becomes...

  • Randomized Controlled Trial of Mindfulness-Based Therapy for Dyspnea in Chronic Obstructive Lung Disease. Mularski, Richard A.; Munjas, Brett A.; Lorenz, Karl A.; Sun, Su; Robertson, Sandra J.; Schmelzer, Wendy; Kim, Adina C.; Shekelle, Paul G. // Journal of Alternative & Complementary Medicine;Oct2009, Vol. 15 Issue 10, p1083 

    Objectives: Patients with chronic obstructive lung disease (COPD) suffer from significant dyspnea and may benefit from complementary and alternative medicine (CAM) therapies aimed at mitigating symptoms. The objective of this study was to test the efficacy of a mindfulness-based breathing...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics